Skip to content

Effects of tetrodotoxin on cue-induced drug craving in abstinent heroin addicts

Effects of tetrodotoxin on cue-induced drug craving in abstinent heroin addicts

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN48774689
Enrollment
45
Registered
2008-07-10
Start date
2008-02-08
Completion date
Unknown
Last updated
2019-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Addiction Mental and Behavioural Disorders Mental and behavioural disorders due to use of opioids

Interventions

The abstinent heroin addicts were randomly assigned to three treatment groups: 1. Placebo 2. 5 µg tetrodotoxin 3. 10 µg tetrodotoxin Eac

Sponsors

The National Basic Research Program of China (973 Program) (China)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Men or non-pregnant/nursing women 18 - 45 years old 2. Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM- IV) criteria for heroin dependence, but opiate-free for at least one month 3. No use of cocaine and other drugs

Exclusion criteria

Exclusion criteria: 1. Current or past cardiovascular disease 2. History of allergy (food, medicine) 3. Current or past psychiatric illness 4. Neurological signs and/or history of neurological disease 5. Current medical illness 6. Participation in other clinical trials of medications within the past three month

Design outcomes

Primary

MeasureTime frame
Cue-induced craving and anxiety. Both the primary and secondary outcomes were measured at 0 minutes (baseline, before TTX administration), 60 minutes (1 hour after TTX administration), 65 minutes (immediately after the first video presentation), 75 minutes (before the second video presentation), and 80 minutes (immediately after the second video presentation).

Secondary

MeasureTime frame
Heart rate and blood pressure. Both the primary and secondary outcomes were measured at 0 minutes (baseline, before TTX administration), 60 minutes (1 hour after TTX administration), 65 minutes (immediately after the first video presentation), 75 minutes (before the second video presentation), and 80 minutes (immediately after the second video presentation).

Countries

China

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026